Literature DB >> 21206982

Functional effects of the MLH1-93G>A polymorphism on MLH1/EPM2AIP1 promoter activity.

Sheron Perera1, Miralem Mrkonjic, James B Rawson, Bharati Bapat.   

Abstract

Defective mismatch repair leads to the microsatellite instability (MSI) phenotype of colorectal cancer (CRC). We previously showed that the MLH1-93G>A promoter polymorphism is strongly associated with MSI tumours, suggesting a modifier role for this polymorphism in CRC. The MLH1 promoter is bi-directional with the EPM2AIP1 gene located on the antisense strand. In order to evaluate the functional effects of this polymorphism, we transfected a panel of CRC, endometrial cancer and non-tumourigenic cell lines with MLH1 luciferase promoter constructs. We used constructs in reverse orientation to assess the effect of this polymorphism on EPM2AIP1. The luciferase activities were compared using a two-sided Student's t-test. Electrophoretic mobility shift assays (EMSAs) were used to evaluate whether differential protein binding was responsible for the differences in promoter activity. We observed a higher level of activity with the -93G allele in all the cell lines observed; including the CRC cell line, HCT116 (P=0.002), the endometrial cancer cell line, HEC-1-A (P<0.001) and the normal colonic cell line, CCD-841-CoTr (P=0.002). This polymorphism also affected EPM2AIP1 transcription with the -93A allele demonstrating higher promoter activity in the HCT116 (P=0.007) and HEC-1-A (P=0.004) cells. The EMSA results suggest that this polymorphism alters the affinity of nuclear factors that bind to this region. Our findings indicate that the -93G>A polymorphism modifies the efficiency of MLH1/EPM2AIP1 transcription.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21206982     DOI: 10.3892/or.2010.1129

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  14 in total

1.  Genome-wide DNA methylation differences according to oestrogen receptor beta status in colorectal cancer.

Authors:  Sonja Neumeyer; Odilia Popanda; Dominic Edelmann; Katja Butterbach; Csaba Toth; Wilfried Roth; Hendrik Bläker; Ruijingfang Jiang; Esther Herpel; Cornelia Jäkel; Peter Schmezer; Lina Jansen; Elizabeth Alwers; Axel Benner; Barbara Burwinkel; Michael Hoffmeister; Hermann Brenner; Jenny Chang-Claude
Journal:  Epigenetics       Date:  2019-03-30       Impact factor: 4.528

2.  Modulation of transcription factor binding and epigenetic regulation of the MLH1 CpG island and shore by polymorphism rs1800734 in colorectal cancer.

Authors:  Andrea J Savio; Bharati Bapat
Journal:  Epigenetics       Date:  2017-03-17       Impact factor: 4.528

3.  The prognostic significance of polymorphisms in hMLH1/hMSH2 for colorectal cancer.

Authors:  Yibaina Wang; Guangxiao Li; Fulan Hu; Haoran Bi; Zhiwei Wu; Xiaojuan Zhao; Ye Li; Shuying Li; Dandan Li; Binbin Cui; Xinshu Dong; Yashuang Zhao
Journal:  Med Oncol       Date:  2014-05-04       Impact factor: 3.064

4.  MLH1 methylation screening is effective in identifying epimutation carriers.

Authors:  Marta Pineda; Pilar Mur; María Dolores Iniesta; Ester Borràs; Olga Campos; Gardenia Vargas; Sílvia Iglesias; Anna Fernández; Stephen B Gruber; Conxi Lázaro; Joan Brunet; Matilde Navarro; Ignacio Blanco; Gabriel Capellá
Journal:  Eur J Hum Genet       Date:  2012-07-04       Impact factor: 4.246

5.  Association of DCC, MLH1, GSTT1, GSTM1, and TP53 gene polymorphisms with colorectal cancer in Kazakhstan.

Authors:  Leyla Djansugurova; Gulnur Zhunussova; Elmira Khussainova; Olzhas Iksan; Georgiy Afonin; Dilyara Kaidarova; M Iqbal Parker
Journal:  Tumour Biol       Date:  2014-09-24

6.  DNA repair and cancer in colon and rectum: Novel players in genetic susceptibility.

Authors:  Barbara Pardini; Alda Corrado; Elisa Paolicchi; Giovanni Cugliari; Sonja I Berndt; Stephane Bezieau; Stephanie A Bien; Hermann Brenner; Bette J Caan; Peter T Campbell; Graham Casey; Andrew T Chan; Jenny Chang-Claude; Michelle Cotterchio; Manish Gala; Steven J Gallinger; Robert W Haile; Tabitha A Harrison; Richard B Hayes; Michael Hoffmeister; John L Hopper; Li Hsu; Jeroen Huyghe; Mark A Jenkins; Loic Le Marchand; Yi Lin; Noralane M Lindor; Hongmei Nan; Polly A Newcomb; Shuji Ogino; John D Potter; Robert E Schoen; Martha L Slattery; Emily White; Ludmila Vodickova; Veronika Vymetalkova; Pavel Vodicka; Federica Gemignani; Ulrike Peters; Alessio Naccarati; Stefano Landi
Journal:  Int J Cancer       Date:  2019-07-04       Impact factor: 7.316

7.  Haplotype defined by the MLH1-93G/A polymorphism is associated with MLH1 promoter hypermethylation in sporadic colorectal cancers.

Authors:  Yasuyuki Miyakura; Makiko Tahara; Alan T Lefor; Yoshikazu Yasuda; Kokichi Sugano
Journal:  BMC Res Notes       Date:  2014-11-24

8.  MLH1-93 G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAFV600E mutation.

Authors:  Lochlan J Fennell; Saara Jamieson; Diane McKeone; Tracie Corish; Megan Rohdmann; Tori Furner; Mark Bettington; Cheng Liu; Futoshi Kawamata; Catherine Bond; Jolieke Van De Pols; Barbara Leggett; Vicki Whitehall
Journal:  BMC Cancer       Date:  2018-01-05       Impact factor: 4.430

9.  MLH1 region polymorphisms show a significant association with CpG island shore methylation in a large cohort of healthy individuals.

Authors:  Andrea J Savio; Mathieu Lemire; Miralem Mrkonjic; Steven Gallinger; Brent W Zanke; Thomas J Hudson; Bharati Bapat
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

10.  Association between MLH1 -93G>a polymorphism and risk of colorectal cancer.

Authors:  Ting Wang; Yang Liu; Li Sima; Liang Shi; Zhaoming Wang; Chunhui Ni; Zhengdong Zhang; Meilin Wang
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.